Table 2.
Number of subjects who experienced at least one common infectious disease (CID) symptom.
| Placebo | Probiotics | |||||
|---|---|---|---|---|---|---|
| Total | 0-28 d | 28-56 d | Total | 0-28 d | 28-56 d | |
| No. of subjects with at least one CID | 19a | 13 | 14b | 10a | 8 | 5b |
| No. of subjects with at least one RI | 10 | 9 | 7 | 2 | ||
| No. of subjects with at least one MS | 9 | 8 | 3 | 1 | ||
| No. of subjects with at least one GI | 6 | 4 | 2 | 2 | ||
The table represents the number of subjects with at least one common infectious disease (CID) symptom during the whole study (total), the treatment period (0-28 days), and the follow-up period (28-56 days). CID are differentiated into the following categories: respiratory (RI), musculoskeletal (MS), and gastrointestinal (GI) symptoms. The difference of total subjects with at least one CID between groups was evaluated using χ2, while the Fisher exact test (with False Discovery Rate adjustment for multiple comparisons) was used for the analysis of the single study periods. Statistically significant results are reported in bold (p value < 0.05). aIndicates the comparison “total in placebo group” vs. “total in probiotic group”; bindicates the comparison “follow-up in placebo group” vs. “follow-up in the probiotic group”.